Sex differences in cancer chemotherapy effects, and why we need to reconsider BSA-based dosing of chemotherapy.
作者信息
Wagner Anna Dorothea
机构信息
Department of oncology, Division of medical oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
出版信息
ESMO Open. 2020 Sep;5(5):e000770. doi: 10.1136/esmoopen-2020-000770.
Abstract
摘要
相似文献
1
Sex differences in cancer chemotherapy effects, and why we need to reconsider BSA-based dosing of chemotherapy.
ESMO Open. 2020 Sep;5(5):e000770. doi: 10.1136/esmoopen-2020-000770.
2
[Body Surface Area Formulas for the Calculation of the Chemotherapy Dosage].
Gan To Kagaku Ryoho. 2017 Nov;44(11):1011-1015.
3
Chemotherapy toxicity in gynecologic cancer patients with a body surface area (BSA)>2 m2.
Gynecol Oncol. 2009 Jul;114(1):53-6. doi: 10.1016/j.ygyno.2009.03.010. Epub 2009 Apr 8.
4
The effect of weight-based chemotherapy dosing in a cohort of gynecologic oncology patients.
Gynecol Oncol. 2015 Jul;138(1):154-8. doi: 10.1016/j.ygyno.2015.04.040. Epub 2015 May 6.
5
Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?
Oncologist. 2007 Aug;12(8):913-23. doi: 10.1634/theoncologist.12-8-913.
6
Standardization of the body surface area (BSA) formula to calculate the dose of anticancer agents in Japan.
Jpn J Clin Oncol. 2003 Jun;33(6):309-13. doi: 10.1093/jjco/hyg062.
7
Chemotherapy dosing part I: scientific basis for current practice and use of body surface area.
Clin Oncol (R Coll Radiol). 2007 Feb;19(1):23-37. doi: 10.1016/j.clon.2006.10.010.
8
Body surface area as a determinant of pharmacokinetics and drug dosing.
Invest New Drugs. 2001 May;19(2):171-7. doi: 10.1023/a:1010639201787.
9
Tolerability of induction chemotherapy dosing practices in acute myeloid leukemia patients.
Leuk Res. 2015 Feb;39(2):173-6. doi: 10.1016/j.leukres.2014.11.024. Epub 2014 Dec 4.
10
Obesity and dose individualization in cancer chemotherapy: the role of body surface area and body mass index.
Med Hypotheses. 2005;65(4):748-51. doi: 10.1016/j.mehy.2005.04.023.
引用本文的文献
1
Sex differences in toxicity and outcomes in patients with sarcoma treated in the perioperative setting at a comprehensive cancer center.
Front Oncol. 2025 Jun 26;15:1585884. doi: 10.3389/fonc.2025.1585884. eCollection 2025.
2
A randomized, double-blind, placebo-controlled phase III study evaluating the preventive effect of diclofenac cream on capecitabine-related hand-foot syndrome: study protocol of J-SUPPORT2401/JORTC-SUP06 (J-DIRECT).
Int J Clin Oncol. 2025 May 14. doi: 10.1007/s10147-025-02789-z.
3
Sex and Gender in Myeloid and Lymphoblastic Leukemias and Multiple Myeloma: From Molecular Mechanisms to Clinical Outcomes.
Curr Oncol. 2025 Mar 31;32(4):204. doi: 10.3390/curroncol32040204.
4
Sex and gender differences in cancer pathogenesis and pharmacology.
Clin Transl Oncol. 2025 Apr 1. doi: 10.1007/s12094-025-03894-1.
5
Sex-related differences in the efficacy and toxicity of cancer treatments.
Clin Transl Oncol. 2025 Mar 28. doi: 10.1007/s12094-025-03893-2.
6
Gender and sex differences in colorectal cancer screening, diagnosis and treatment.
Clin Transl Oncol. 2025 Jan 17. doi: 10.1007/s12094-024-03801-0.
7
Gene regulatory networks reveal sex difference in lung adenocarcinoma.
Biol Sex Differ. 2024 Aug 6;15(1):62. doi: 10.1186/s13293-024-00634-y.
8
Hand-foot syndrome in cancer patients on capecitabine: examining prevalence, impacts, and associated risk factors at a cancer centre in Malaysia.
Support Care Cancer. 2024 May 14;32(6):345. doi: 10.1007/s00520-024-08490-7.
9
Long-term Musculoskeletal Consequences of Chemotherapy in Pediatric Mice.
Function (Oxf). 2024 Mar 7;5(3):zqae011. doi: 10.1093/function/zqae011. eCollection 2024.
10
A life-course approach to tackling noncommunicable diseases in women.
Nat Med. 2024 Jan;30(1):51-60. doi: 10.1038/s41591-023-02738-1. Epub 2024 Jan 19.
本文引用的文献
1
Gender medicine and oncology: report and consensus of an ESMO workshop.
Ann Oncol. 2019 Dec 1;30(12):1914-1924. doi: 10.1093/annonc/mdz414.
2
Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study.
Lancet. 2019 Oct 5;394(10205):1254-1263. doi: 10.1016/S0140-6736(19)31792-1. Epub 2019 Aug 22.
3
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.
Lancet Oncol. 2019 May;20(5):663-673. doi: 10.1016/S1470-2045(18)30915-X. Epub 2019 Mar 25.
4
Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade.
Nat Med. 2019 Jan;25(1):141-151. doi: 10.1038/s41591-018-0221-5. Epub 2018 Nov 12.
5
Association of Patient Sex With Chemotherapy-Related Toxic Effects: A Retrospective Analysis of the PETACC-3 Trial Conducted by the EORTC Gastrointestinal Group.
JAMA Oncol. 2018 Jul 1;4(7):1003-1006. doi: 10.1001/jamaoncol.2018.1080.
6
Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients.
Br J Haematol. 2017 Nov;179(3):410-420. doi: 10.1111/bjh.14860. Epub 2017 Oct 8.
7
Sex differences in immune responses.
Nat Rev Immunol. 2016 Oct;16(10):626-38. doi: 10.1038/nri.2016.90. Epub 2016 Aug 22.
8
Comprehensive Characterization of Molecular Differences in Cancer between Male and Female Patients.
Cancer Cell. 2016 May 9;29(5):711-722. doi: 10.1016/j.ccell.2016.04.001.
9
Sexual dimorphism in cancer.
Nat Rev Cancer. 2016 May;16(5):330-9. doi: 10.1038/nrc.2016.30. Epub 2016 Apr 15.
10
Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial.
Eur J Cancer. 2015 Nov;51(16):2453-64. doi: 10.1016/j.ejca.2015.06.123. Epub 2015 Aug 10.
Zotero 插件